Morell-photoA leading Professor from the British Heart Foundation who specialises in the treatment of cardiac and lung disease will visit the University of Lincoln to deliver a one-off lecture this month.

Professor Nick Morrell, British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge, runs a dedicated research laboratory studying the genetics and molecular basis of rare but important cardiovascular diseases, particularly Pulmonary Arterial Hypertension (PAH), and is developing new treatments for these conditions.

Professor Morrell will visit the University of Lincoln on Tuesday 27th October 2015 to present his pioneering work in this area. Entitled ‘From genetics to new therapies in Pulmonary Arterial Hypertension’, the talk will take place at 2pm in the EMMTEC Lecture Theatre on the Brayford Pool Campus. It is free to attend and is open to students, staff and members of the public.

PAH is a chronic and debilitating disease that affects the blood vessels in the lungs, leading to heart failure, and leaves sufferers feeling breathless and exhausted. Current treatments only target the symptoms and prognosis remains poor. The only effective cure is a lung, or heart and lung, transplant, which has associated risks and complications.

Professor Morrell and his research team are investigating why lung blood vessels narrow in people suffering from PAH, and how this narrowing might be prevented or reversed.

He has worked closely with Dr Rajiv Machado from the University of Lincoln’s School of Life Sciences, who is also recognised for his expertise in the study of cardiovascular disease.

Together they conducted extensive research into a protein which targets the effects of a faulty gene, offering the first potential treatment for the major genetic cause of PAH. Their study was supported by funding from the British Heart Foundation, and examined genetic evidence dating back to 2000.

Dr Machado said: “We are delighted to welcome Professor Morrell to the University of Lincoln. He is at the forefront of determining the defects underlying pulmonary hypertension on both a genetic and functional level and crucially, his work is immediately translational, in that the science emerging from his laboratory is of direct relevance to the patient population.”